ForexProsThe Exchange Rates are powered by Forexpros - The Leading Financial Portal.

RESX: Update on Third Quarter Financials

November 22, 2015 | By | Reply More

The company had approximately $ 14.6 million in cash and cash equivalents at the end of the third quarter of 2015. RestorGenex is planning to develop RES-529 as a treatment for both wet AMD and GBM. For wet AMD, two Phase 1 clinical trials have been performed with RES-529.

Options News and Information on Yahoo! Finance

Tags: , , , ,

Category: Options

Leave a Reply